Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. (Q39100916)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Miles C Andrews

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

S Parakh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Murphy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

D Lau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

10 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pharmacy and Therapeutics

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

121-123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25382067%20AND%20SRC:MED&resulttype=core&format=json

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Determinants of BRAF mutations in primary melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Mutation-driven drug development in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

BRAFV600E detection in melanoma is highly improved by COLD-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Effect of vemurafenib on a V600R melanoma brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

BRAF inhibitor activity in V600R metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12229